SKSahar Khastar

Sahar Khastar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sahar Khastar has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Abhishek Kumar

    School of Pharmacy-Adarsh Vijendra Institute of Pharmaceutical Sciences, Shobhit University, Gangoh, India

    1 shared publication
  • Ata Fateh

    Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran

    1 shared publication
  • Beneen Husseen

    Medical Laboratory Technique College, The Islamic University, Najaf, Iraq

    1 shared publication
  • Deepak Nathiya

    Department of Pharmacy Practice, Institute of Pharmacy, Nims University Rajasthan, Jaipur, India

    1 shared publication
  • Irwanjot Kaur

    Department of Biotechnology and Genetics, Jain (Deemed-to-Be) University, Bengaluru, India

    1 shared publication
  • Jaya Bansal

    Department of Applied Sciences, Chandigarh Engineering College, Chandigarh Group of Colleges, Jhanjeri, Mohali, India

    1 shared publication

Latest Publications

  • Long Non-Coding RNAs in Non-Alcoholic Fatty Liver Disease; Friends or Foes?

    by Sina Kalantari Soltanieh, Sahar Khastar, Irwanjot Kaur, Abhishek Kumar, Jaya Bansal, Ata Fateh, Deepak Nathiya, Beneen Husseen, Mansour Rajabivahid, Mahmoud Dehghani-Ghorbi, et al.

    Metabolic dysfunction-associated fatty liver disease (MAFLD) is a range of conditions that start with the accumulation of fat in the liver (hepatic steatosis) and can progress to more severe stages like steatohepatitis (NASH) and fibrosis without drinking alcohol. Environmental and genetic variables both contribute to MAFLD’s development, with various biological processes and mediators involved at every phase. Long non-coding RNAs (lncRNAs) are a class of RNA molecules that are not translated into protein and are over 200 nucleotides long. They can impact genes that encode protein by controlling transcriptional and post-transcriptional procedures. Dysregulation of lncRNA has been connected to several liver diseases, including MAFLD. Recent research has linked lncRNAs to MAFLD pathology in both patients and animal models. However, the roles of most lncRNAs in MAFLD pathology are still not well recognized. This review provides a comprehensive catalog of recently reported lncRNAs in the pathogenesis of MAFLD and summarizes the current knowledge of lncRNAs usage as therapeutic strategies in MAFLD, the most common liver disease. Collectively, lncRNA’s targeting could potentially offer a therapeutic approach by modulating MAFLD.